Amiselimod

• Description:

  Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases[1][2][3][4].

• Product Name Alternative:

  MT-1303

• UNSPSC:

  12352005

• Target:

  LPL Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/amiselimod.html

• Smiles:

  FC(F)(C1=CC(CCC(CO)(CO)N)=CC=C1OCCCCCCC)F

• Molecular Formula:

  C19H30F3NO3

• Molecular Weight:

  377.44

• References & Citations:

  [1]Sugahara K, et al., Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174 (1) :15-27.|[2] Kappos L, et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM) : a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15 (11) :1148-59. |[3]Shimano K, et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells. PLoS One. 2019 Dec 5;14 (12) :e0226154. |[4]Sugahara K, et al. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models. J Immunol Res. 2019 Dec 23;2019:5821589.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  942399-20-4